Company / SG&A Expense
Neogen SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$201.2M
FY2025
5-year range
$40.8M / $218.2M
FY2021-FY2025
Trend
-7.8%
vs FY2024
Sector context
#108 of 158
Health Care
What the data says
At $201M, Neogen's sg&a expense ranks #51 of 158 in the Health Care sector.
Based on SEC 10-K filings.
$201M in FY2025 with a 5-year CAGR of +39.3%.
Remained stable around $201M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +65.6%
- 5-Year CAGR
- +39.3%
- 10-Year CAGR
- -
Sector benchmark
#51 of 158 in Health CareTop 32% of 158This company $201.2M Sector average $175.9B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +39.3%, indicating consistent growth.
- In FY2025, sg&a expense decreased 7.8% year-over-year.
- Ranks #108 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.86 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $201.2M | -7.8% |
| FY2024 | $218.2M | +9.1% |
| FY2023 | $199.9M | +350.9% |
| FY2022 | $44.3M | +8.7% |
| FY2021 | $40.8M | +6.5% |
| FY2020 | $38.3M | +11.9% |
| FY2019 | $34.2M | +17.2% |
| FY2018 | $29.2M | +15.7% |
| FY2017 | $25.2M | +3.2% |
| FY2016 | $24.4M | +20.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026